NCT03091192 2026-01-23Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT03081858 2025-06-27Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder CancerLipac Oncology LLCPhase 1/2 Completed15 enrolled 16 charts
NCT03636256 2023-08-14Evaluation of NanoDoceĀ® in Participants With Urothelial CarcinomaNanOlogy, LLCPhase 1/2 Completed36 enrolled 18 charts
NCT01310803 2017-10-05Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderEndo PharmaceuticalsPhase 3 Terminated1 enrolled 5 charts
NCT00753415 2015-03-17A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)Merck Sharp & Dohme LLCPhase 1 Completed37 enrolled 10 charts
NCT02006667 2015-02-11A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial CancerHoffmann-La RochePhase 2 Completed13 enrolled 12 charts
NCT02013765 2014-09-25A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial CancerHoffmann-La RochePhase 2 Terminated5 enrolled 12 charts